Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Shares Outstanding (Entity) of $158.7 million for Q1 2026, up 9.23% year-over-year from $145.3 million in Q1 2025, and up 1.58% quarter-over-quarter from $156.2 million in Q4 2025.
Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Shares Outstanding (Entity) for 10 consecutive years, with $158.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 9.23% year-over-year to $158.7 million; the TTM figure through Mar 2026 stood at $158.7 million (up 9.23% YoY), while the FY2025 annual figure was $156.2 million, up 8.29% from the prior year.
- Shares Outstanding (Entity) improved to $158.7 million in Q1 2026 per DNLI's latest filing, from $156.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $158.7 million in Q1 2026 and bottomed at $122.9 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $140.1 million across 5 years, with a median of $142.5 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 1.34% — and 2023, when it climbed 11.53%.
- Denali Therapeutics' Shares Outstanding (Entity) stood at $136.0 million in 2022, then climbed by 1.78% to $138.4 million in 2023, then rose by 4.22% to $144.2 million in 2024, then increased by 8.29% to $156.2 million in 2025, then climbed by 1.58% to $158.7 million in 2026.
- Business Quant data shows DNLI's Shares Outstanding (Entity) at $158.7 million in Q1 2026, $156.2 million in Q4 2025, and $146.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 187.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.31 Mn |
| Mar 31, 2026 | 186.64 Mn |
| Dec 31, 2025 | 172.65 Mn |
| Sep 30, 2025 | 172.42 Mn |
| Jun 30, 2025 | 171.45 Mn |
| Mar 31, 2025 | 171.22 Mn |
| Dec 31, 2024 | 164.47 Mn |
| Sep 30, 2024 | 169.46 Mn |
| Jun 30, 2024 | 168.83 Mn |
| Mar 31, 2024 | 149.40 Mn |
| Dec 31, 2023 | 137.37 Mn |
| Sep 30, 2023 | 137.64 Mn |
| Jun 30, 2023 | 137.05 Mn |
| Mar 31, 2023 | 136.52 Mn |
| Dec 31, 2022 | 125.53 Mn |
| Sep 30, 2022 | 123.47 Mn |
| Jun 30, 2022 | 123.01 Mn |
| Mar 31, 2022 | 122.67 Mn |
| Dec 31, 2021 | 121.52 Mn |
| Sep 30, 2021 | 121.74 Mn |